Karyopharm Therapeutics | KPTI - Trade Debtors


Karyopharm Therapeutics reported $26.18M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
AbbVie USD 12.59B 180M Dec/2025
Abbott USD 11.22B 655M Mar/2026
Amgen USD 9.14B 432M Mar/2026
AstraZeneca USD 17.88B 1.17B Mar/2026
BioCryst Pharmaceuticals USD 106.82M 15.49M Dec/2025
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Eli Lilly USD 21.18B 1.02B Mar/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
GlaxoSmithKline GBP 7.94B 178M Mar/2026
Incyte USD 1.05B 27.09M Mar/2026
J&J USD 22.54B 1.21B Mar/2026
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
MacroGenics USD 10.42M 2.95M Mar/2026
Merck USD 11.78B 345M Dec/2025
Nektar Therapeutics USD 1.78M 1.12M Dec/2025
Novartis USD 9.6B 2.69B Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
Pfizer USD 16.17B 332M Mar/2026
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Roche Holding CHF 11.9B 460M Dec/2025
Sangamo BioSciences USD 581K 110K Jun/2024
Takeda JPY 876.35B 118.43B Mar/2026
Tectonic Therapeutic USD 0 270K Dec/2023
TG Therapeutics USD 392.05M 86.42M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Xencor USD 12M 17.3M Mar/2026